Invite: Expert Access: Barclays KOL call: Bayer Litigation Endgame: Legal Expert View Ahead of Key Court Rulings

Research evidence excerpt

Invite: Expert Access: Barclays KOL call: Bayer Litigation Endgame: Legal Expert View Ahead of Key Court Rulings

and corporate integrity agreements. He has appeared before numerous US District Courts

and Courts of Appeals throughout the country, the Main Justice at the DOJ, US attorneys'

district offices throughout the country, and the main Washington and district offices of the

FBI and the Office of the Inspector General at the US Department of Health and Human

Services.

Meet the Analysts

Charles Pitman-King joined Barclays in 2022 as a VP in the

European pharmaceutical team to cover a selection of

mid-cap companies. His previous experience includes

covering both mid-cap European and large-cap US

pharmaceutical companies since 2018, as well as broad

sector themes, such as the rapidly evolving COVID-19

pandemic and sector ESG themes. Prior to this, he has also

had experience covering the Aerospace and Defence

sector, and working in financial modelling. He holds a first

class Masters in Mathematics from Durham University and

has been a CFA charterholder since 2019.

View Analyst Page

Note: Barclays does not provide legal advice. Any oral or written presentation by an external

lawyer to Barclays’ clients does not create an attorney-client relationship or involve the

rendering of legal advice. The views or opinions expressed by an external speaker do not

necessarily reflect the views of Barclays, and are provided for informational purposes only.

Barclays is not responsible for, and has not independently verified, the information provided

by any external speaker and Barclays makes no representation that such information is

correct, complete, or reliable for any purpose

European Pharmaceuticals, Biotechnology & Life Sciences

Charles Pitman-King, CFA

+44 (0)20 3134 6023